Cartilage Diseases

• EMA withdrawal · 2026-04-15
  EMA Application withdrawn: Jelrix — TETEC Tissue Engineering Technologies AG

  EMA has withdrawn the Jelrix application from TETEC Tissue Engineering Technologies AG. The product targeted knee injuries and cartilage dis…

• EMA approval · 2025-03-03
  EMA Authorised: Spherox (spheroids of human autologous matrix-associated chondrocytes) — CO.DON Gmbh

  The EMA authorised Spherox, comprising spheroids of human autologous matrix-associated chondrocytes, for cartilage diseases.

• EMA withdrawal · 2017-01-12
  EMA Withdrawn: ChondroCelect (characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins) — TiGenix N.V.

  The EMA has withdrawn ChondroCelect, a therapy using autologous cartilage cells expanded ex vivo, from the market.

• CLINICAL_TRIALS trial_result · 2009-02-04
  Clinical Trial Update: Sampling Biomarkers in Meniscus Injury to the Knee

  A completed clinical trial investigating sampling biomarkers in knee meniscus injury related to cartilage diseases.